MOTS-c is supplied strictly as a research chemical for in vitro and laboratory investigation only; it is not a drug, supplement, or food, and it is not intended for human or veterinary use.
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is one of a small family of peptides encoded not in nuclear DNA but inside the mitochondrial genome itself. Its discovery reframed a long-standing assumption in cell biology: that the mitochondrion is a downstream effector of nuclear instructions rather than a source of signaling molecules in its own right. For researchers, MOTS-c is interesting less as a single-target ligand and more as a probe for retrograde signaling — the flow of information from the mitochondrion back to the nucleus. This guide summarizes what preclinical work has reported about its origin, its proposed mechanisms, and the experimental contexts in which it has been studied.
Reviewed for research accuracy — 30 July 2026.
A peptide encoded inside the mitochondrial genome
MOTS-c is a 16-amino-acid peptide (MRWQEMGYIFYPRKLR) translated from a short open reading frame located within the mitochondrial 12S rRNA gene. That location is what makes it unusual. Mitochondria use a genetic code distinct from the nuclear one and were, until relatively recently, thought to encode only the 13 core subunits of the oxidative phosphorylation machinery plus structural RNAs. MOTS-c belongs to a set of small peptides — the mitochondrial-derived peptides, or MDPs — that appear to be encoded in overlapping or alternative reading frames within that same compact genome.
Whether MOTS-c is translated in the mitochondrial matrix or in the cytosol from a cytoplasmic transcript remains an open question in the literature, and different groups have argued both positions. What is better established is that the peptide is detectable in tissue and in circulation in animal models and in human plasma, and that its measured levels are not static — they shift with metabolic state, with age, and with acute physiological stress in the models studied.
The folate–AICAR–AMPK axis
The mechanism most consistently reported for MOTS-c in preclinical research runs through one-carbon metabolism rather than through a classical cell-surface receptor. In the original characterization work, metabolomic profiling of treated cells and animals indicated that MOTS-c is associated with interference in the folate cycle, which in turn appears to slow de novo purine biosynthesis. Because AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) is an intermediate in that pathway, the reported consequence is AICAR accumulation — and AICAR is a well-characterized endogenous activator of AMP-activated protein kinase (AMPK).
AMPK is the cell’s canonical low-energy sensor. Research suggests that this indirect route — folate cycle inhibition leading to AICAR accumulation leading to AMPK activation — is how MOTS-c exerts a broad influence on cellular energy handling in the systems examined, including reported shifts in glucose utilization and fatty-acid oxidation markers in cultured myocytes and in rodent tissue. Investigators studying MOTS-c should note that this places it upstream of a very widely connected signaling hub, which makes clean attribution of any single downstream readout difficult.
Retrograde signaling and nuclear translocation
A second line of work has examined what MOTS-c does under metabolic stress. Studies indicate that in response to stressors such as glucose restriction or oxidative challenge, MOTS-c translocates to the nucleus, where it has been observed to associate with stress-responsive transcription factors including ATF1 and NRF2 and with antioxidant response elements in the promoters of nuclear genes. In those experiments, the peptide appears to participate in regulating a transcriptional program — not simply to act as a metabolic modulator in the cytosol.
That finding is the reason MOTS-c is frequently described in the literature as evidence for mitochondrial-to-nuclear retrograde signaling: a peptide encoded by the mitochondrial genome that physically relocates to the nucleus and is associated with changes in nuclear gene expression. For researchers designing experiments, this dual localization means subcellular fractionation and immunofluorescence timing matter a great deal; a whole-cell readout may average away the compartment-specific behavior that is the actual phenomenon of interest.
Exercise as an experimental stimulus
Much of the interest in MOTS-c within exercise physiology comes from observations that its levels are dynamic rather than fixed. Preclinical and limited human work has reported that acute exercise is associated with increased MOTS-c in skeletal muscle and in circulation, positioning it as a candidate exercise-responsive mitochondrial signal. Rodent studies have also examined administration alongside exercise protocols and reported associations with skeletal-muscle performance measures and with markers of muscle homeostasis in aged animals.
Human data remain limited and largely observational — measurements of endogenous plasma MOTS-c across age groups, fitness levels, and metabolic states, rather than controlled intervention trials. No conclusions about human outcomes can responsibly be drawn from that evidence base, and researchers citing it should be explicit about the observational nature of the measurements.
Genetic variant research
A naturally occurring mitochondrial variant, m.1382A>C, produces a single amino-acid substitution in the MOTS-c sequence (K14Q). This variant is essentially absent in European populations but present at appreciable frequency in some Northeast Asian populations, which has made it a target for association studies in Japanese cohorts. Reported associations have been examined in the context of longevity and metabolic phenotypes, with mixed and sex-dependent results. The variant is useful to researchers mainly as a natural experiment: it allows the peptide’s sequence to be varied in humans without intervention, and comparative in vitro work on the K14Q form versus wild-type MOTS-c is an active area.
MOTS-c among the mitochondrial-derived peptides
MOTS-c is one member of a small group. The table below summarizes how the characterized MDPs are described in the research literature.
| Peptide | Encoding region | Length | Mechanisms reported in research | Evidence base |
|---|---|---|---|---|
| MOTS-c | 12S rRNA gene ORF | 16 aa | Folate cycle interference → AICAR accumulation → AMPK activation; nuclear translocation with ATF1/NRF2 | Cell culture, rodent models, limited observational human measurement |
| Humanin (HN) | 16S rRNA gene ORF | 24 aa | Studied for cytoprotective signaling in vitro, including reported interaction with BAX and with an IL-6-family receptor complex | Extensive in vitro and rodent literature; earliest-described MDP |
| SHLP 1–6 (small humanin-like peptides) | 16S rRNA gene, alternative frames | 20–38 aa | Heterogeneous; SHLP2 and SHLP3 most characterized, examined for effects on mitochondrial respiration markers in cell models | Primarily in vitro; sparse compared with HN and MOTS-c |
The practical distinction for study design: humanin and the SHLPs are generally investigated as cytoprotective signals, whereas MOTS-c is most often investigated as a metabolic and transcriptional regulator. They are not interchangeable positive controls for one another.
Laboratory handling and solution arithmetic
Research-grade MOTS-c is supplied as a lyophilized powder. As a short, unmodified, relatively hydrophilic sequence it is generally soluble in bacteriostatic or sterile water for laboratory stock preparation, and standard peptide practice applies: store the lyophilized vial cold and protected from light, avoid repeated freeze–thaw of reconstituted stock, and aliquot rather than re-puncturing a single working vial.
Stock concentration is straightforward arithmetic. A 10 mg vial brought up in 2 mL of diluent yields 5 mg/mL, so a 100 µL aliquot contains 500 µg of peptide; the same vial in 5 mL yields 2 mg/mL. For other vial sizes and target concentrations, the peptide reconstitution calculator handles the conversion. Because MOTS-c work frequently involves quantitative metabolomic or transcriptional endpoints, identity and purity documentation matters more than usual — third-party analysis for catalog items is published in the COA library.
What the evidence does not support
Three honest limitations are worth stating plainly. First, the endogenous physiological role of MOTS-c is still contested, including basic questions about where it is translated and what its circulating concentrations actually are — immunoassay-based measurements across studies have been inconsistent. Second, nearly all mechanistic findings come from cell culture and rodent models at concentrations that may not reflect endogenous exposure. Third, there is no controlled human interventional literature of any meaningful size, so any extrapolation from these mechanisms to human physiology is speculation rather than inference.
References
- Lee C, Zeng J, Drew BG, et al. Cell Metabolism. 2015;21(3):443–454. PMID: 25738459. (Original characterization of MOTS-c and the folate–AICAR–AMPK axis; title omitted.)
- Kim KH, Son JM, Benayoun BA, Lee C. MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018;28(3):516–524.e7. PMID: 29983246.
- Reynolds JC, Lai RW, Woodhead JST, et al. Nature Communications. 2021;12(1):470. PMID: 33473109. (MOTS-c as an exercise-responsive mitochondrial-encoded regulator in rodent models; title omitted.)
- Fuku N, Pareja-Galeano H, Zempo H, et al. Aging Cell. 2015;14(6):921–923. PMID: 26289118. (m.1382A>C / K14Q variant association work in Japanese cohorts; title omitted.)
- Reviews of the mitochondrial-derived peptide family, including humanin and the small humanin-like peptides (SHLP1–6), have been published in the physiology and endocrinology literature; readers are directed to PubMed searches for “mitochondrial-derived peptides” for current coverage, as specific identifiers are not asserted here.
- Human measurement studies of circulating MOTS-c across age and metabolic status are observational and heterogeneous in assay methodology; findings should be read as association data only.
For research use only. MOTS-c described here is a laboratory reagent intended solely for in vitro and preclinical investigation by qualified researchers. It is not a drug, supplement, cosmetic, or food, is not approved by any regulatory authority for human or veterinary use, and must not be administered to humans or animals.